Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07089576 · ClinicalTrials.gov registry record · NA
Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA
A NA study of Aortic Arch Aneurysm and Aortic Arch Dissection, sponsored by Artivion.
- Recruiting
- Registry status
- NA
- Development phase
- 132
- Enrollment target
- 10
- Study locations
NCT07089576: Recruiting NA study of Aortic Arch Aneurysm and Aortic Arch Dissection, sponsored by Artivion.
NCT07089576 is a NA study of Aortic Arch Aneurysm and Aortic Arch Dissection that is actively recruiting participants, run by Artivion. The registered enrollment target is 132 participants, below the 501-participant average among 4 other Aortic Arch Aneurysm trials with a reported enrollment target (74% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07089576, a NA study of Aortic Arch Aneurysm and Aortic Arch Dissection, is actively recruiting participants, sponsored by Artivion.
- RECRUITING
- Registry status
- NA
- Development phase
- 132 participants
- Enrollment target
- 10
- Study locations
Study Summary
The goal of this clinical trial is to learn if the Arcevo LSA stent graft can safely and effectively treat patients that have an acute or chronic aortic dissection and/or aneurysm that involves the aortic arch and the descending thoracic aorta, with or without the involvement of the ascending aorta.
Primary Outcome
The major adverse events included in the composite are: * All-cause mortality * New permanent disabling stroke * New permanent paraplegia and/or paraparesis * Unanticipated aortic reoperation in the treated segment * LSA occlusion
Conditions Studied
Interventions
- DEVICE Arcevo™ LSA Hybrid Stent Graft System
Study Locations (10)
New York
- Columbia University Irving Medical Center/New York Presbyterian Hospital - New York
- Montefiore Medical Center - The Bronx
Texas
- University of Texas - Austin - Austin
- Baylor Scott & White - Plano
California
- University of Southern California - Los Angeles
Georgia
- Emory University School of Medicine - Atlanta
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
Maryland
- Johns Hopkins Hospital - Baltimore
Ohio
- Cleveland Clinic Foundation - Cleveland
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2025-11-04 |
| Est. Completion | 2032-07 |
| Phase | NA |
What NCT07089576 shows while recruiting
NCT07089576 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 501-participant average among 4 other Aortic Arch Aneurysm trials with a reported enrollment target (74% lower).
The record links to 4 conditions, with Aortic Arch Aneurysm appearing as the primary indexed condition, and to 1 intervention - of which Arcevo™ LSA Hybrid Stent Graft System is the first listed.
NCT07089576 lists 10 locations in 8 states (New York, Texas, California).
Frequently Asked Questions
What is clinical trial NCT07089576 about?
NCT07089576 is a clinical study titled "Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA". The goal of this clinical trial is to learn if the Arcevo LSA stent graft can safely and effectively treat patients that have an acute or chronic aortic dissection and/or aneurysm that involves the aortic arch and the descending thoracic aorta, with or without the involvement of the ascending aorta.
What is the current status of trial NCT07089576?
This trial is currently recruiting. It is a NA study. The enrollment target is 132 participants. The study started on 2025-11-04. Estimated completion is 2032-07.
What conditions does trial NCT07089576 study?
This clinical trial studies the following conditions: Aortic Arch Aneurysm, Aortic Arch Dissection, Acute Aortic Dissection, Chronic Aortic Dissection.
What interventions are being tested in trial NCT07089576?
The interventions under investigation include: Arcevo™ LSA Hybrid Stent Graft System (DEVICE).
Who is sponsoring clinical trial NCT07089576?
This trial is sponsored by Artivion, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07089576 being conducted?
This trial has 10 study locations across California, Georgia, Illinois, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aortic Arch Aneurysm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms
RECRUITING · NA
-
CAAAs, TAAAs, Aortic Arch Aneurysms or Dissections With Fenestrated/Branched Stent Graft
RECRUITING · NA
-
Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies
RECRUITING · NA
-
Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI